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Background/Objective: The aim of the study was to estimate the rate of evolution or for
multiple sclerosis (MS), after a first acute demyelinating event (ADE) in pediatric patients,
and to investigate the variables that predict this evolution.
Methods: We retrospectively evaluated the clinical and neuroradiological features of
children who presented a first ADE between January 2005 and April 2017. All patients
included underwent a baseline MRI, a cerebrospinal fluid and blood analysis, including
virological examinations. The evolution into MS was determined by the 2013 International
Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria. Clinical and radiological
features predictive of MS were determined using multivariate analyses.
Results: Ninety-one patients were selected (mean age at onset: 10.11 ± 4.6). After
a mean follow-up of 5.6 ± 2.3 years, 35% of patients’ conditions evolved to MS. In
the logistic multivariate analysis of clinical and laboratory data, the best predictors of
evolution into MS were: the presence of oligoclonal bands in CSF (p < 0.001), past
infection with EBV (p < 0.001), periventricular lesions (p < 0.001), hypointense lesions
on T1 (p < 0.001), and lesions of the corpus callosum (p < 0.001) including Dawson
fingers (p < 0.001).
Conclusion: Our findings suggest that a pattern of neuroimaging and laboratory findings
may help to distinguish between, at clinical onset, children with a monophasic syndrome
(clinically isolated syndrome or acute disseminated encephalomyelitis) from those who
will develop MS.
Keywords: multiple sclerosis, acute demyelinating event, pediatrics, clinically isolated syndrome, acute
disseminated encephalomyelitis
INTRODUCTION
The term “acquired demyelinating syndrome” (ADS) is used to indicate the first clinical
episode of acute CNS demyelination, which can either represent the sentinel attack
of an underlying chronic demyelinating disorder or remain monophasic. Pediatric ADS
occurs with an incidence of 0.5–1.66 per 100,000 children (1–5). The proportion of ADS
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children who are ultimately diagnosed with MS ranges between
15 and 45% in different studies (2, 3, 5–7). An early differential
diagnosis between a monophasic demyelinating inflammatory
syndrome and multiple sclerosis is crucial, as increasing evidence
favors early initiation of disease-modifying therapy (2, 8–
11). Early treatment avoids the accumulation of disability,
delays the transition from “relapsing-remitting” into “secondary
progressive MS,” and prevents axonal damage from occurring at
an early stage (12, 13). Therefore, an early diagnosis of MS in
children can slow down disease progression and reduce the level
of future disability in adulthood (14). In recent years, studies
have focused on defining criteria for early diagnosis in children
and adolescents, as well as focusing on searching for predictive
markers of progression into the recurrent disease (2, 5, 8–10).
However, these studies have some limits: (1) the incidence of
multiple sclerosis varies in different cohorts (15–46%), because
different inclusion criteria are applied, even based on MRI
findings alone, without considering clinical symptoms/signs (2,
4–6, 15); (2) some studies include patients aged between 16
and 18 years, thus leaving childhood unexplored (5, 7); (3) it
is difficult to distinguish between patients with ADEM from
MS patients with ADEM-like onset, at the time of the first
attack (7, 8, 10, 16); and (4) predictors with high specificity
and positive predictive value show low sensitivity (5, 7, 17). The
present study aims: (1) to analyze the clinical and neuroimaging
features of a pediatric population at ADS onset; (2) to identify
possible predictors of progression into MS; and (3) to compare
the predictors obtained from our results with those of previous
studies.
MATERIALS AND METHODS
Participants and Inclusion Criteria
We performed a retrospective study that included all ADS
patients that were referred to the Neurology Unit of the Bambino
Gesù Children Hospital and the Department of Pediatrics of
the Sapienza University, between January 2005 and April 2017.
The records of a total of 156 patients with suspected ADS were
reviewed (Figure 1). The inclusion criteria were: (1) a history of
an acute neurological event suggestive of central nervous system
(CNS) inflammatory demyelinating disease not attributable to
other conditions (infectious, metabolic, neoplastic, congenital or
vascular illness); (2) a clinical follow-up of at least 1 year; (3)
age at onset ≤16 years; (4) available laboratory and clinical data
at onset (clinical symptoms according to EDSS classification,
serum, and cerebrospinal fluid (CSF) examinations, serology
for EBV); and (5) brain and spinal MRI at onset and during
follow-up.
Patients with secondary causes of demyelination (of toxic,
genetic, metabolic, infectious, neoplastic), neuromyelitis
optica spectrum disorders (NMOSD), ADS with serum
positivity for myelin oligodendrocyte glycoprotein antibodies
(MOGAbs) or a history of a progressive disease course were
excluded.
In order to overcome the limitations of previously reported
studies, we selected: (1) patients with CIS, ADEM, and MS
diagnosed according to the 2013 International Pediatric Multiple
Sclerosis Study Group (IPMSSG) criteria (18), which refers to the
2010 McDonald criteria for neuroradiological dissemination in
time (DIT), and space (DIS) (10), (2) both patients with ADEM
and CIS at onset; and (3) patients with a maximum onset age of
16 years.
The distinction between monophasic ADEM and multiphasic
ADEM and MS with ADEM-like onset was made according to
the 2013 IPMSSG criteria (18).
Diagnosis of NMOSD were made according to the
“International consensus diagnostic criteria for neuromyelitis
optica spectrum disorders” of 2015 (19). Patients with core
clinical features of NMOSD (optic neuritis, acute myelitis or area
postrema syndrome) were all tested for serum anti-aquaporin-4
antibodies (AQP4-ab).
The study was approved by the Ethical Committee of Bambino
Gesù Children Hospital.
Data Collection
The MRI, CSF, and clinical data were collected. An MRI was
acquired using a 1.5T magnet or 3T magnet (Samsung), both
available in two participating centers. We ensured that the
brain MRI, performed at the onset, included axial and sagittal
T2-weighted, fluid-attenuated inversion recovery (FLAIR)-
weighted, T1-weighted MRI sequences, and T1-weighted
MRI images after administration of gadolinium. All patients
included in the study also underwent a spinal MRI at the onset
of symptoms and before the start of corticosteroid therapy;
dual-echo (proton-density and T2-weighted) conventional
and/or fast spin-echo, STIR (as alternative to proton-density-
weighted) and contrast-enhanced T1-weighted spin-echo (in
case of presence of T2 lesions) sequences were acquired. The
MRI scan revision was centralized and carried out by two
operators (a clinician [LP] and a neuroradiologist [LFT]),
blinded to clinical outcome, at the Bambino Gesù children’s
hospital. Lesion characteristics were recorded, including
the location, distribution, border outline, symmetry, and
number, as well as size and gadolinium capture. Tumefactive
lesions were defined as such if larger than two cortical gyri.
The presence or absence of black holes (non-enhancing
hypointense lesions visible on T1-weighted sequences) and
post-gadolinium enhancement were analyzed. Follow-up
brain and spine MRI (performed after a minimum period
of 3 months from baseline) were also reviewed in order to
assess the neuroradiological dissemination in time (DIT) and
space (DIS).
CSF examination data at onset included the cell count
and the search for oligoclonal bands (OCBs). The presence
of OCBs was determined by isoelectric focusing, combined
with immunoblotting of matched serum, and CSF sample
pairs. Virological assessments consisted of measuring serum
viral antibodies (IgM and IgG by ELISA) and performing
quantitative real-time PCR for the Epstein Barr virus
(EBV).
The presence of MOGAbs was assessed only in patients that
were observed since 2015, when we started performing MOGAbs
detection by cell-based assays (CBAs).
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FIGURE 1 | Study profile.
Statistical Analysis
Statistical analyses were completed using SPSS software (version
22.0). Descriptive statistics were used to compare the difference
in frequencies in the MS group (clinical, laboratory, and MRI
subtypes) and the non-MS groups (including CIS and ADEM).
The Pearson’s chi squared test for nominal categorical variables
(e.g., sex, fever) and the Mann-Whitney U-test for continuous
variables (e.g., age in months) were used. Logistic regression
analyses were used to assess whether clinical, biochemical and
MRI features of the initial attack could be predictors of evolution
toward MS.
We used themultivariate logistic regression to build predictive
models of evolution toward MS. As a first step, we selected
the variables to test their single risk value (odd ratio-OR)
in the univariate logistical analysis. Then, the variables that
individually showed a significant OR (p < 0.05), were tested
in the multivariate logistic analysis to build the models. In the
multivariate logistic analysis, we used a backwards elimination
process to test the correlation (p value cut-off = 0.10 for
exclusion from the model) between variables, and calculated
the sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) for each model built for the
diagnosis of MS. Significance was fixed at p < 0.05. A multiple-
comparison post-hoc correction was made with the Bonferroni
correction, setting the significance cut-off at α/n with α= 0.05.
The current criteria available for pediatric age and those used
in our models, were compared by using a univariable generalized
linear model, with a logit link function, and a binomial error
distribution.
RESULTS
During the considered time interval, only 102 out of the 156
patients initially identified were included in the analysis. The
main reasons for exclusion from the study were: lack of follow-
up data as to whether evolution into MS had taken place (25
patients), MRI exams that did not meet the requirements (lack
of sequences, lack of spine MRI) (15 patients), secondary forms
of demyelination (infections, genetic) (eight patients), and lack
of laboratory data (six patients). Thirty-five patients presented
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features of ADEM, five with features of NMOSD, 57 with CIS,
and five patients with features suggesting MS at onset.
Among 36 patients undergoing anti-MOGAbs detection,
six (16.6%) showed positive results. Since anti-MOGAbs seem
to have a protective role against MS development (20–22),
none of the MOGAbs positive patients conditions evolved
into MS and data from MOGAbs-positive patients and
children with NMOSD were excluded from the statistical
analysis, aimed at looking for factors predicting evolution
into MS.
Ninety-one patients (42 females and 49 males; mean age
at onset: 10.11 ± 4.60) who presented the first ADS in the
observation period and met the remaining inclusion criteria
were recruited (Figure 1). Onset diagnosis included 33 patients
with ADEM, 53 patients with CIS, and five patients with MS at
first ADS. The mean follow-up duration was 5.6 ± 2.3 years.
During follow-up, the patients underwent clinical and MRI
controls every 4–6 months during the first year of illness, and
then with annual frequency. Patients with a normal MRI at
onset and after 2 years, or those whose MRI became normal
during the first 2 years of follow-up, without evolution to MS,
discontinued MRI controls after 2 years and continued only
a clinical follow-up. In case of a recurrence, the patient was
clinically evaluated and underwent an MRI examination for
the relapse. It is noteworthy to underline that the follow-up
duration was similar in all patients, regardless of the clinical
evolution.
First ADS: Comparison Between ADEM
and CIS Patients
At onset ADEM was diagnosed in 33 patients (36.3%), while 53
patients (58.2%) were classified as CIS. The main differences in
clinical and neuroradiological features at onset between CIS and
ADEM patients are summarized in Table 1. Five patients (5.4%)
presented clinical and neuroradiological findings suggestive of
MS at onset.
In CIS patients, 18 patients (34%) clinically presented optic
neuritis, 10 patients (18.9%) presented transverse myelitis, and
14 patients (20.8%) presented polyfocal symptoms, while 11
patients (20.8%) presented other monofocal symptoms. All
ADEM patients presented encephalopathy. Other neurological
signs or symptoms in ADEM patients, involved the pyramidal
(57.6%), cerebellar (54.5%), the brainstem (33.3%), and the
proprioceptive (30.3%) systems. The optic nerve was involved
in 21.2% of ADEM patients, while 6.1% of patients showed
sphincter dysfunction.
Patients with ADEM (mean age of 7.6 ± 3.7 years) were
younger than those with CIS (mean age: 11.1 ± 3.5 years)
(p< 0.001) and more often had a history of recent infection (63.6
vs. 28.3%; p < 0.005), fever at onset (33.3 vs. 11.3%; p < 0.05),
and cerebellar symptoms/signs (54.5 vs. 11.3%; p < 0.001).
Sensory disorders were more frequent in CIS than in ADEM
patients (32.1 vs. 9.1%; p < 0.05). CSF pleocytosis was more
frequent in ADEM than CIS (51.5 vs. 28.3%; p< 0.005) andOCBs
were more frequently detected in CIS than in ADEM patients
(49.1 vs. 15.2%; p < 0.001).
TABLE 1 | Baseline clinical and demographic characteristics of ADEM and CIS
patients.
ADEM PATIENTS
Female sex (%) 42.4
Age at onset (Mean age, SD) 7.7 ± 3.7 yrs
History of recent infection (%) 63.6
Fever at onset (%) 33.3
Oligoclonal Bands (%) 15.2
Evidence of past EBV infection (%) 48.5
Pathological MRI (%) 100
Evolution into MS (%) 21.2
CIS PATIENTS
Female sex (%) 45.3
Mean age (Mean age, SD) 11.2±3.5
History of recent infection (%) 28.3
Fever at onset (%) 11.3
Oligoclonal Bands (%) 49.1
Evidence of past EBV infection (%) 54.7
Pathological MRI (%) 71.7
CIS topography: Evolution into MS
Optic Neuritis (n, %) 19 (35.8) 3/19 (15.7)
Brainstem 13 (24.6) 6/13 (46.1)
Spine 10 (18.9) 1/13 (7.7)
Other cerebral syndromes 11 (20.7) 9/11 (81.8)
Clinical Follow-up: MS vs. Non-MS Patients
Thirty-one patients (35%) evolved to MS, while the remaining
60 patients (65%) neither showed further demyelinating episodes
nor neuroradiological relapses. While MS was diagnosed in seven
out of 33 ADEM patients (21.2%) included in the analysis, 18
out of 53 patients with an initial diagnosis of CIS evolved to MS
(34%). However, this difference was not significant (p > 0.05).
Patients evolving to MS were more often female (66.7 vs. 33.3%;
p < 0.01) and older (12.4 ± 3.4 vs. 8.9 ± 3.8; p < 0.01) in
comparison with non-MS patients.
The survival curve of the total patients is shown in Figure 2.
The evolution to MS occurred mostly within 2 years of onset and
did not occur in any patients after 3.75 years. CIS patients evolved
to MS more rapidly than ADEM patients, but the final evolution
times were equal for both groups (Figure 3).
CSF oligoclonal bands were positive in 73.3% of patients with
MS (OR 9.23; p < 0.001) and there was evidence of past infection
by EBV (IgG) in 86.7% of MS patients (OR11.52; p < 0.001)
(Table 2). Interestingly, serum anti-EBV IgG were detected in
100% of the ADEM patients who evolved to MS, and only in
34.6% of monophasic ADEM (p < 0.001). On the contrary, a
recent infection represented a protective factor for the evolution
to MS (OR 0.18; p < 0.01).
In patients withMS diagnosis at onset (2 females and 3males),
1 out of 5 cases (20%) clinically presented optic neuritis, 1 out
of 5 cases (20%) with polyfocal symptoms in, and 3 out of 5
cases (33.3%) of monofocal symptoms. Four patients were aged
over 16 and only one patient was younger. The MRI at the
onset showed the presence of multifocal lesions. In particular,
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FIGURE 2 | Kaplan-Meier survival analysis with event of interest “diagnosis of MS.” Censored patients (not converted into MS at last follow-up) are indicated on the
curves. Time of diagnosis of MS is reported in months. The time axis is right-censored at 10 years. Evolution into MS occurred for most patients within 24 months
from the onset and in no patient after 3.75 years.
FIGURE 3 | Kaplan-Meier survival analysis with event of interest “diagnosis of MS” comparing the survival curves of CIS and ADEM patients. Censored patients (not
converted into MS at last follow-up) are indicated on the curves. Time of diagnosis of MS is reported in months. The time axis is right-censored at 10 years. The MS
rate of evolution into MS is significantly faster for CIS than ADEM patients. However, both groups convert into MS within 24 months. Log rank test χ2 4.97, p < 0.05.
periventricular lesions were present in 5 out of 5 patients (100%),
while juxtacortical lesions were present in 1 out of 5 cases
(20%), and infratentorial lesions in 3 out of 5 cases (33.3%),
and spine lesions in 3 out of 5 cases (33.3%). All five patients
had a simultaneous presence of capturing and non-capturing
gadolinium lesions at the onset MRI.
MRI Lesions: MS vs. Non-MS Patients
In comparison with non-MS children and adolescents, in MS
patients, MRI lesions were more frequently located in the
periventricular (OR 12.5; p < 0.001) and subcortical (6.17;
p = 0.001) regions, the corpus callosum (OR 25; p < 0.001), the
brainstem (OR 3.8; p < 0.01), and the cerebellar peduncles (OR
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TABLE 2 | Onset clinical and neuroradiological features predictive of progression to MS (Univariate Analysis Logistics).
Frequency in MS vs. not MS (%) Univariate analysis odds ratio (CI) Sign. p-value
CLINICAL FEATURES
CIS 61.3 vs. 55 (p = 0.06) 2.61 (0.91–6.92) 0.06
ADEM 22.6 vs. 43.3(p = 0.06) 0.41(0.15–1.09) 0.056
Sex F 66.7M 33.3 vs. F 36.1M 63.9 (p < 0.01) 3.54 (1.41–8.91) per female sex <0.01
Age 12.4 ± 3.4 vs. 8.9 ± 3.8 (p < 0.01) 1.29 (1.12–1.48) <0.01
Comorbidities 16.7 vs. 8.2 (p = 0.19) 2.24 (0.59–8.43) 0.23
Recent infection 16.7 vs. 63.2 (p < 0.01) 0.18 (0.06–0.53) <0.01
Fever 3.3 vs. 26.2 (p < 0.01) 0.09 (0.01–0.77) <0.05
Encephalopathy 26.7 vs. 42.6 (p = 0.15) 0.49 (0.18–1.27) 0.14
Pyramidal 53.3 vs. 44.3 (p = 0.44) 1.43 (0.59–3.46) 0.41
Brainstem 36.7 vs. 18.1 (p = 0.06) 2.63 (0.97–7.07) 0.055
PPT Sensitivity 36.7 vs. 16.4 (p = 0.03) 2.95 (1.08–8.07) 0.06
Proprioceptive 33.4 vs. 14.8 (p = 0.04) 2.88 (1.02–8.15) 0.06
Cerebellar 36.7 vs. 24.6 (p = 0.17) 1.77 (0.69–4.56) 0.23
Optic neuritis 16.7 vs. 41 (p = 0.17) 0.28 (0.09–0.85) <0.05
Bowel and Blurred 0 vs. 13.1 (p = 0.03) 0.01(0.00–0.01) 0.99
OGB present 73.3 vs. 23.1 (p < 0.01) 9.23 (3.37–25.23) <0.001
Pleocytosis 40.2 vs. 41.3 (p = 0.55) 0.96 (0.39–2.34) 0.928
EBV IgM 0 vs. 8.2 (p = 0.128) 0.01 (0.00–0.01) 0.999
EBV IgG 86.7 vs. 36.1 (p < 0.01) 11.52 (3.55–37.32) <0.001
EBV pcr 16.7 vs. 6.6 (p = 0.12) 2.85 (0.7–11.51) 0.142
MRI FEATURES
Brain MRI with lesions 97.2 vs. 72.3 (p = 0.01) 9.13 (1.14-73.1) 0.03
LOCATION
Periventricular 73.3 vs. 18 (p < 0.001) 12.5 (4.42–35.35) <0.001
Subcortical 80 vs. 39.3 (p < 0.001) 6.17 (2.19–17.3) 0.001
Subtentorial 66.7 vs. 41 (p = 0.01) 2.88 (1.15–7.18) 0.02
Spine 43.3 vs. 29.5 (p = 0.14) 1.82 (0.73–4.52) 0.19
Deep WM 83.3 vs. 52.5 (p = 0.31) 4.53 (1.53–13.39) <0.01
Cortical 3.3 vs. 21.3 (p = 0.02) 0.12 (0.01–1.02) 0.05
Corpus callosum 73.3 vs. 9.8 (p < 0.001) 25 (7.83–81.1) <0.001
Internal capsule 13.3 vs. 16.4 (p = 0.26) 0.78 (0.22–2.74) 0.71
Basal Ganglia -Thalamus 0 vs. 23 (p = 0.02) 0.01 (0.00–0.01) 0.923
Brainstem 53.3 vs. 23 (p < 0.01) 3.8 (1.5–9.75) <0.01
Cerebellar hemispheres 46.7 vs. 18 (p < 0.01) 3.2 (0.9–9.4) 0.071
Cerebellar peduncles 33.3 vs. 11.4 (p = 0.01) 2.88 (1.02–8.15) 0.04
Optic nerve 17.6 vs. 82.4 (p = 0.11) 0.37 (0.09–1.41) 0.147
Thalamus 10 vs. 25.4 (p = 0.27) 0.32 (0.08–1.23) 0.09
DISTRIBUTION
Dawson Finger 43.3 vs. 1.6 (p < 0.001) 45.8 (5.59–376.19) <0.001
Asymmetrical WM 93.3 vs. 65.6 (p < 0-005) 7.35 (1.59–33.89) 0.01
Symmetrical WM 60.1 vs. 39.3 (p = 0.05) 2.31 (0.94–5.64) 0.06
Asymmetrical GM 16.7 vs. 21.3 (p = 0.41) 0.64 (0.22–1.88) 0.42
Symmetrical GM 6.7 vs. 31.1 (p < 0.01) 0.15 (0.03–0.73) 0.05
MORPHOLOGY
Poorly demarcated edges 46.7 vs. 67.2 (p = 0.03) 0.42 (0.17–1.04) 0.06
Well limited edges 83.3 vs. 29.5 (p < 0.001) 11.9 (3.95–36.12) <0.001
Black holes 33.3 vs. 1.6 (p < 0.001) 30 (3.61–249.1) <0.01
Tumefactive lesions 33.3 vs. 1.6 (p = 0.43) 0.83 (0.33–2.05) 0.692
Gad positive lesions 73.3 vs. 34.4 (p < 0.001) 5.23 (1.99−13.76) 0.001
T1 hypointhense lesions 66.7 vs. 4.9 (p < 0.001) 38.66 (9.66–154.72) <0.001
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2.88; <0.05). With regard to the distribution and morphology of
the lesions, asymmetric WM lesions (OR 7.35; p = 0.01), lesions
perpendicular to the corpus callosum known as “Dawson fingers”
(OR 45.8; p < 0.001), lesions with well-limited margins (OR
11.9; p < 0.001), black holes (OR 30; p < 0.01), and gadolinium
enhancing lesions (OR 5.23; p= 0.001) were more frequent in the
MS group than in non-MS patients.
MOGAbs Positive Patients
Among the 36 patients undergoing MOGAbs detection, six
(16.6%) showed positive results. At the onset, these patients
presented clinical MRI features of ADEM (2 patients, 33.3%),
unilateral retrobulbar optic neuritis (RON) (one patient, 16.6%),
bilateral RON (2 patients, 33.3%), and longitudinal extensive
transverse myelitis (LETM) (one patient, 16.6%). No patient
with a diagnosis of MS at onset showed positivity for MOGAbs.
During the follow-up, no patient with positive anti-MOGAbs
showed evolution to MS. One patient with ADEM presented
a clinical and neuroradiological relapse which resulted in them
being included in the multi-phase ADEM group. The remaining
patients had a monophasic course.
Models of ADS Evolution Into MS
In the multivariate logistic analysis (Table 3), the best
combination of non-neuroradiological features predictive
of progression into MS included: (1) the absence of a recent
infection (OR 0.21, CI 0.05-0.79; p = 0.02), (2) OCBs in CSF
(OR 8.34, CI 2.5-27.7; p = 0.001), and (3) past EBV infection
(OR 11.47, CI 2.5-27.76; p < 0.001). However, the absence
of a recent infection was excluded from the model after the
Bonferroni correction. The definitive predictive model could
predict evolution into MS with a sensitivity of 66, a specificity of
93, a positive predicting value (PPV) of 83, a negative predicting
value (NPV) of 85, and an accuracy of 93.4%.
With regard to the MRI data, we found that an abnormal
brain MRI was associated with a higher risk of evolution into MS
(97.2% of patients) than a normal brain MRI (e.g., isolated optic
neuritis or myelitis) (OR 9.13, p < 0.05). The most important
MRI baseline features for predicting evolution into MS were: (1)
at least one Dawson finger (OR 15.42, CI 1.13-209.73; p = 0.01),
2) at least one periventricular lesion (OR 12.42, CI 2.83-54.58;
p < 0.001), and (3) at least one T1 hypointense lesion (OR 25.48,
CI 4.5-144.22; p <0.001). The model showed a sensitivity of 76.2,
a specificity of 100, a PPV of 100, an NPV of 87.4, and an accuracy
of 91%. A secondMRI model that combined good sensitivity and
specificity included: (1) at least one periventricular lesion (OR
26.82, CI 2.64-271.98; p = 0.005), (2) at least one subcortical
lesion (OR 13.17, CI 1.3-133.2; p < 0.05), (3) at least one lesion
of the corpus callosum (OR 9, CI 1.6-0.84; p = 0.01), and (4)
at least one T1 hypointense lesion (OR 17.54, CI 2.57-119.72;
p= 0.003). However, the variable “at least one subcortical lesion”
was removed from themodel after the Bonferroni correction. The
definitive model showed a sensitivity of 80, a specificity of 96, a
PPV of 92, an NPV of 90, and an accuracy of 96.7%.
The multivariate analysis of the combined non-
neuroradiological and MRI findings, showed that the MRI
features that best distinguished patients evolving into MS, from
those that would not evolve into MS were: (1) at least one
periventricular lesion (OR 10.13, CI 2.26-45.33; p < 0.01), (2)
at least one T1 hypointense lesion (OR 45.34, CI 7.43-276.69;
TABLE 3 | Results of multivariate analysis.
Model Odds ratio (CI) P value Sensibility, specificity,
PPV, NPV, and accuracy
NOT NEURORADIOLOGICAL (ALL REQUIRED)
OCB IgG positivity in CSF OR 9.4 (2.96–29.83) 0.001 66%; 93%; 83%; 85%; 93.4%
Serum EBV IgG positivity OR 11.77 (3.18–43.24) <0.001
1st NEURORADIOLOGICAL (ALL REQUIRED)
At least one Dawson Finger OR 15.42 (1.13–209.73) 0.01 76.2%; 100%; 100%; 87.4%; 91%
At least one periventricular lesion OR 12.42 (2.83–54.58) <0.001
At least one T1 hypointense lesion OR 25.48 (4.5–144.22) <0.001
2nd NEURORADIOLOGICAL (ALL REQUIRED)
At least one corpus callosum lesion OR 8.87 (1.89–41.67) <0.005 80%; 96%; 92%; 90%; 96.7%
At least one periventricular lesion OR 11.64 (2.51–54.01) <0.005
At least one T1 hypointense lesion OR 29.74 (4.91–180.16) <0.001
LABORATORY AND NEURORADIOLOGICAL (ALL REQUIRED)
OCB IgG positivity in CSF OR 4.8 (1.16–20.49) <0.01 75%, 92%, 87%, 84.2%, 88.5%.
At least one periventricular lesion OR 10.13 (2.26–45.33) <0.01
At least one T1 hypointense lesion OR 45.34 (7.43–276.69) <0.001
*LABORATORY AND NEURORADIOLOGICAL (ALL REQUIRED)
Serum EBV IgG positivity OR 32.65, CI 8.36–231.76 <0.001 60%, 100%, 100%, 89.6%, 90.9%.
At least one periventricular lesion OR 4.5, CI 1.23–16.72 <0.01
At least one T1 hypointense lesion OR 25.18 CI 6.56–135.87 <0.001
*Only for MS with ADEM like onset.
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p < 0.001), and (3) the presence of OCBs (OR 4.8, CI 1.16-20.49;
p < 0.01). This model showed a sensitivity of 80, a specificity of
92, a PPV of 87, an NPV of 84.2, and an accuracy of 88.5%.
The results of the comparison between the current MRI
criteria and our neuroradiological models are featured inTable 4.
DISCUSSION
This is the first study conducted on a population of Italian ADS
patients, with the aim of finding predictive factors of evolution
into MS. We found that the MS risk is high in CIS and ADEM
patients, whose MRI shows lesions of the corpus callosum and
of the periventricular regions, T1 hypointense lesions, and whose
clinical data reveal the presence of OCBs, and a past infection by
EBV.
In comparison with previous findings [Mikaeloff et al., 2004;
(6–8, 10, 16)], the present study has the following strengths: (1)
the use of the recent IPMSSG 2013 criteria for the diagnosis ofMS
and other demyelinating disorders, (2) the exclusive inclusion of
early onset MS patients (maximum age of 16 years at onset), and
(3) the research into MS predictors valid for both patients with
ADEM and CIS-like onset.
In the pediatric age range, MS can be difficult to predict at
the time of the first ADS, especially in very young children.
In 2007, the IPMSSG proposed provisional definitions for
pediatric acquired demyelinating disorders of the CNS (23).
The revised McDonald criteria deals with MS diagnosis in
children on the basis of studies providing further insight into
clinical, CSF and MRI features (10). However, all versions
of the McDonald diagnostic criteria are based on studies in
patients with MS onset in adulthood. Although the diagnostic
ability of the 2010 McDonald criteria in children is similar
to that in adults (10, 24, 25), caution must be taken when
applying the 2010 criteria to children aged younger than 11
years (10). Considering these limits, in 2013 the IPMSSG
decided to revise the diagnostic criteria in order to facilitate
the diagnosis of inflammatory demyelinating diseases in children
(18).
Can ADEM Evolve Into MS?
Using the IPMSSG 2013 criteria in our patients, we found that
the overall risk of MS after an initial inflammatory demyelinating
event was 35%, in line with data reported in the previous case
series (21–57%) (1–3, 5, 15).
Our results show that the onset phenotype (ADEM or CIS)
did not determine the risk of evolution to MS. In particular,
in our ADEM patients, the risk of progression to MS was
21.2%, similar to that reported in previous studies (10–29%)
(1–3, 11, 26)]. This means that not only patients with CIS
but also those with a first ADEM-like ADS can develop MS.
Our findings support the recent concept of a partial overlap
between ADEM and MS, especially in pediatric patients. The
IPMSS 2013 criteria focusses on this overlap, considering
the possibility of a diagnosis of MS after a first episode of
ADEM (26).
Clinical, Laboratory, and MRI Predictors
Concerning the evolution toMS, we found that a recent infection
represented a protective factor (OR 0.124; p = 0.01), since
most of the patients with a recent infection (63.2%) did not
evolve to MS. In most cases, the infections involved the upper
respiratory or gastrointestinal tract, and were associated with
viral or bacterial agents that could not be identified by means
of serological tests. The protective role of a recent infection
in patients with ADS has also been described in a previous
TABLE 4 | Current criteria compared with our models in our cohort.
Criteria KIDMUS 2004 McDonald2005
(Barkhof)
Callen per
MS 2009
Callen MS
vs. ADEM
2009
McDonald
2010 DIS
Verhey 2011 I model II model
Features Two of two: -lesions
perpendicular to the
long axis of the corpus
callosum - well-defined
lesions
Three of four: ≥9
T2 lesions o 1 gad
+ lesion ≥3
periventricular ≥1
subtentorial ≥1
subcortical
Two of three:
≥5 T2 lesion
≥2
periventricular
≥1 brainstem
Two of three
-no diffuse
bilateral
lesions -
black holes
-≥1
brainstem
lesion
Two of four
≥1
periventricular
≥1
subcortical
≥1
subtentorial ≥
1spine
Two of two:
≥1
periventricular
≥1 T1
hypointhense
Dawson
Finger ≥1
periventricular
lesion ≥1 T1
hypointhense
lesion
≥1
Periventricular
lesion ≥1
Corpus
callosum
lesion ≥1 T1
hypointhense
lesion
Sensibility 21–47% 56–91% 26–74% 95% 85–100% 70–84%
95% CI 38.5% 56% 45% 16% 85% 80% 76% 80%
Specificity 98-100% 30-100 % 68-100% 90% 80–86%* 90–93%
95% CI 100% 85% 90% 100% 61% 91.4% 100% 96%
PPV 82–100% 34–69% 37-97% 71% 76%* 76%
95% CI 100% 70% 60% 100% 58% 85% 100% 92%
NPV 61–87% 40–98% 90–91% 99% 100%* 96%
95%CI 74% 77% 70% 76% 88% 91% 87% 90%
Bold figures refer to criteria applied to our cohort.
*Children under the age of 12.
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FIGURE 4 | Representative MRI scans. (A) Axial T2 Flair MRI of a 15-year-old girl featuring Dawson’s finger lesions (yellow arrows); (B) axial T2 Flair MRI, and (C) axial
T1 MRI of a 16-year-old girl showing periventricular (red arrows) and corpus callosum (green arrow) lesions, and T1 hypointense lesions.
study (4). We can therefore hypothesize that, in patients with
a recent infection, demyelinating lesions are probably due
to a transient, and self-limited post-infectious immunological
response (27).
In the present study, previous infection with EBV,
documented by serum IgG positivity, was associated with
an increased risk of progression to MS (OR 11.52; p < 0.001).
In particular, serum anti-EBV IgG positivity was detected in
100% of ADEM patients evolving to MS, and in only 34.6% of
ADEM patients with monophasic disease (p < 0.001). Previous
studies have shown that serum anti-EBV IgG is more frequently
found in children with MS (85–88%) than in healthy individuals
(44–77%) (28–31). The role of EBV in the pathogenesis of MS
in not clearly understood, but several hypotheses have been
proposed (32, 33). MS may be the result of the ability of EBV to
establish a persistent brain infection in persons predisposed to
develop the disease, allowing EBV-infected B cells to accumulate
in the CNS (32). A deficiency in CD8+ effector memory T cells,
reported in MS patients (33), may explain a possible impairment
in EBV infection control (34).
Our results underline the importance of OCB detection in
children and adolescents with a first ADS. In our patients, OCB
positivity in the CSF was an important predictor of the evolution
to MS (OR 9.23; p < 0.001). Although the presence of OCB is
not pathognomonic for MS, as OCBs are detected in 8–15% of
ADS children who will not develop MS (2, 11, 26), the presence
of OCB in the CSF should be considered a strong predictor of MS
evolution (35). In adult MS patients, the presence of oligoclonal
bands increases the risk of clinically definite multiple sclerosis
[adjusted hazard ratio 1.3 (1.0–1.8)] and of disability [adjusted
hazard ratio 2.0 (1.2–3.6)], regardless of other factors (36). In a
recent pediatric prospective study, OCBs were positive in 70%
of MS patients (20). While OCB positivity was excluded from
the 2010 criteria, in the latest 2017 version of the McDonald
criteria, the presence of OCBs is considered a criterion for DIT
(37).
Previous studies have shown that anti-MOGAbs can be found
in pediatric patients with ADEM and NMOSD (22) and have a
protective influence against developingMS (20–22). In our study,
anti-MOGAbs were found in 16.6% of patients tested, none of
which presented an evolution to MS.
Considering the brain and spine MRI at the onset in
our cohort, neuroradiological features that showed the highest
specificity with the highest predictive value of evolution into
MS included: (1) at least one Dawson finger, (2) at least one
periventricular lesion, and (3) at least one hypointense lesion
on T1 (Figure 4). However, this model had low sensitivity
(76.2%), probably because of a low incidence of Dawson fingers
in pediatric MS, in particular at the onset of the disease (38).
Dawson fingers, attributed to inflammation around the long axis
of medullar veins, are considered highly specific for multiple
sclerosis (38), so they are included in the KIDMUS (Kids with
Multiple Sclerosis) criteria (5). Recently, a large prospective
study found that one or more T1 hypointense lesions and T2
periventricular lesions are strongly associated with a diagnosis of
MS in children (20).
In order to obtain good sensitivity and specificity, we built
a second model that included: (1) at least one periventricular
lesion, (2) at least one lesion of the corpus callosum, and
(3) at least one T1 hypointense lesion (Figure 4). This model
showed a specificity of 96, a sensitivity of 80, and an accuracy
of 96.7%. While the presence of periventricular lesions and T1
hypointense lesions have already been included in a previous
study (6), lesions of the corpus callosum, regardless of their
morphology, have never been considered in the previous
pediatric diagnostic criteria. Our data are supported by a study
showing a predictive value of corpus callosum lesions (HR 0.16
CI 0.03-0.89; p= 0.04) (4).
The main limitation of our study is represented by its
retrospective design. In particular, this negatively affected the
total number of recruited patients. However, in order to obtain
reliable results, we analyzed variables that could be available in
all patients. Future prospective studies will hopefully validate the
predictive models proposed in this paper.
Conclusions
This is the first study to assess the risk of evolution into MS
in an Italian pediatric population at a first ADS. In comparison
with the 2010 McDonald criteria, both neuroradiological
models proposed in our study have the advantage of being
independent of the age at onset and of ADEM-like onset.
Moreover, our first neuroradiological model showed the same
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high specificity and PPV as KIDMUS (100%), but had
better sensitivity (76.2 vs. 38%). The sensitivity was increased
further in our second model (80%), which maintained a high
specificity (96%).
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